The synthetic κ-opioid agonist (-)U50,488 does not affect calcium transport into R1.1 mouse thymoma cell line

International Journal of Immunopharmacology

Volumn 21, Issue 2, 1999, Pages 133-140

  Martin Kleiner, I ^a   Bidlack, J M ^b  

^a RUDER BO KOVI INSTITUTE   (Croatia)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Calcium transport; Kappa; Mouse thymoma; Opioid

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; CALCIUM 45; CONCANAVALIN A; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; PHYTOHEMAGGLUTININ; PLANT LECTIN;

ANIMAL CELL; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; DOSE RESPONSE; GENE EXPRESSION; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; THYMOMA; TUMOR CELL LINE;

EID: 0033060945     PISSN: 01920561     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0192-0561(98)00075-7     Document Type: Article

References (19)

1. Belkowski, S.M., Zhu, J., Liu-Chen, L-Y., Eisenstein, T.K., Adler, M.W., & Rogers, T.J. (1995). Sequence of K-opioid receptor cDNA in the R1.1 thymoma cell line. J. Neuroimmunol., 62, 113-117.
2. Bidlack, J.M., Saripalli, L.D., & Lawrence, D.M.P. (1992). K-opioid binding sites on murine lymphoma cell line. Europ. J. Pharmacol., 227, 257-265.
3. Caroleo, M.C., Arbitrio, M., Melchiorri, D., & Nistico, G. (1994). A reappraisal of the role of the various opioid receptor subtypes in cell-mediated immunity. Neuroimmunomodul., 1, 141-147.
4. Densmore, J.J., Szabo, G., & Gray, L.S. (1992). A voltage-gated calcium channel is linked to the antigen receptor in Jurkat T lymphocytes. FEBS Letters, 312, 161-164.
5. Gardner, P. (1989). Calcium and T lymphocyte activation, Cell., 59, 15-20.
6. Gross, R.A., & MacDonald, R.L. (1987). Dynorphin A selectively reduces a large transient (N-type) calcium current of mouse dorsal root ganglion neurons in cell culture. Proc. Natl. Acad. Sci. U.S.A., 84, 5469-5473.
7. Gross, R.A., Moises, H.C., Uhler, M.D., & MacDonald, R.L. (1990). Dynorphin A and cAMP-dependent protein kinase independently regulate neuronal calcium currents. Proc. Natl. Acad. Sci. U.S.A., 87, 7025-7029.
8. Guan, L., Townsend, R., Eisentstein, T.K., Adler, M.W., & Rogers, T.J. (1994). Both T cells and macrophages are targets of K-opioid induced immunosuppression. Brain Behav. Immun., 8, 229-240.
9. Guan, L., Eisenstein, T.K., Adler, M.W., & Rogers, T.J. (1997). Inhibition of T cell superantigen responses following treatment with the K-opioid agonist U50, 488H. J. Neuroimmunol., 75, 163-168.
10. Hemmick, L.M., & Bidlack, J.M. (1987). β-Endorphin modulation of mitogen-stimulated calcium uptake by rat thymocytes. Life Sci., 41, 1971-1978.
11. Hess, S.D., Oortgiesen, M., & Cahalan, M.D. (1993). Calcium oscillations in human T and natural killer cells depend upon membrane potential and calcium influx. J. Immunol., 150, 2620-2633.
12. + mouse lymphoma. Immu-nogenetics, 3, 75-84.
13. Kimball, P.M., Gamaz. N., & Sell, S. (1988). Two episodes of calcium uptake associated with T-lymphocyte activation. Cell. Immunol., 113, 107-116.
14. Lawrence, D.M.P., & Bidlack J.M. (1993). The kappa opioid receptor expressed on the mouse R1.1 thymoma cell line is coupled to adenylyl cyclase through a pertussis toxin-sensitive guanine nucleotide-binding regulatory protein. J. Pharmacol. Exp. Therap., 266, 1678-1683.
15. Prete, P., Levin, E.R., Pedram, A. (1986). The in vitro effect of endogenous opiates on natural killer cells, antigen-specific cytolytic T cells, and T-cell subsets. Exp. Neurol., 92, 349-359.
16. +-lymphomas: sensitivity to cortisol and phytohemagglutinin. J. Immunol., 110, 1470-1475.
17. Rogers, T.J., Guan, L,. Alicea, C., Belkowski, S., Zhu, J., Liu-Chen, L.-Y., Eisenstein, T.K., & Adler, M.W. (1996) Kappa receptor mRNA in cells of the murine immune system. J. Neuroimunol., 69, 10-11.
18. 2+ uptake and glutamate release in rat cerebral cortex in primary culture. J. Neurochem., 68, 517-524.
19. 45Ca into rat cortical synaptosomes by inhibiting N- but not L-type calcium channels. Neuropharmacol., 29, 439-444.